Intravascular Large B-Cell Lymphoma (IVLBCL) is a subtype of large B-cell lymphoma, characterized by large tumor B-cells aggregating inside blood vessels. This disease is extremely rare and highly malignant, often involving the central nervous system, lungs, and skin. Its prognosis is poor and clinical treatment challenging. At the recently concluded 28th European Hematology Association (EHA) Annual Meeting, a study (Abstract Number: P1185) from Dr. Daobin Zhou's team at Peking Union Medical College Hospital was selected. This study evaluated the efficacy and safety of the Zanubrutinib combined with R-CHOP regimen in treating initial IVLBCL, attracting widespread attention. To further understand this study, the Oncolgy Fronter invited Dr. Zhou for a detailed interpretation and analysis, summarized as follows:
IVLBCL is a rare type of aggressive B-cell lymphoma that does not form a tumor mass. Its diagnosis is difficult and lacks an established standard treatment. Zanubrutinib is a novel Bruton kinase inhibitor. Recent studies have shown that Zanubrutinib has good therapeutic effects in B-cell lymphomas originating from activated B-cells, those with dual expression, and those with MYD88 mutations.
